Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS
Authors:
- Crislaine Aparecida da SilvaCSCrislaine Aparecida da Silva
- Liliane Silvano AraújoLALiliane Silvano Araújo
- Maria Luíza Gonçalves dos Reis MonteiroMMMaria Luíza Gonçalves dos Reis Monteiro
- Lívia Helena de Morais PereiraLPLívia Helena de Morais Pereira
- Marcos Vinícius da SilvaMSMarcos Vinícius da Silva
- Lúcio Roberto Cançado CastellanoLCLúcio Roberto Cançado Castellano
- Marlene Antônia dos ReisMRMarlene Antônia dos Reis
- Juliana Reis MachadoJMJuliana Reis Machado
Open Access
- 2 May 2019
- journal article
- research article
- Published by Wiley in Disease Markers
- Vol. 2019, 1-6
Abstract
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are primary glomerulopathies leading to proteinuria, known as podocytopathies, which share syndromic and morphological similarities. Morphological similarity occurs in cases of FSGS in which the sclerotic lesion was not sampled in renal biopsy, due to the focal nature of the disease. Differentiating these entities is very important, especially in cases of suspected FSGS but with sclerotic lesion not sampled, as they are diseases that apparently have different pathogenic mechanisms and prognosis. The difference in uPAR expression in situ among these two entities may be related to a distinct molecular mechanism involved in pathogenesis. Thus, finding biomarkers involved in the pathogenesis and that can also help in differential diagnosis is very relevant. The aim of this work was to evaluate the potential of urokinase-type plasminogen activator receptor (uPAR) as a biomarker in renal biopsies of patients with podocytopathies (). Immunohistochemistry showed that FSGS () had increased uPAR expression in podocytes compared with both the MCD group (; ) and control group (; ). ROC curve () showed that this biomarker has 80.95% of specificity in biopsies of patients with FSGS. Therefore, uPAR presented a high specificity in cases of podocytopathies associated with sclerosis and it can be considered a potential biomarker for FSGS.
Keywords
Funding Information
- Fundação de Ensino e Pesquisa de Uberaba
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
This publication has 33 references indexed in Scilit:
- An Overview of Molecular Mechanism of Nephrotic SyndromeInternational Journal of Nephrology, 2012
- Soluble urokinase receptor and focal segmental glomerulosclerosisCurrent Opinion in Nephrology and Hypertension, 2012
- Educational paperEuropean Journal of Pediatrics, 2012
- Podocyte Disorders: Core Curriculum 2011American Journal of Kidney Diseases, 2011
- The glomerulus – a view from the outside – the podocyteThe International Journal of Biochemistry & Cell Biology, 2010
- Regulation of cell signalling by uPARNature Reviews Molecular Cell Biology, 2010
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Modification of kidney barrier function by the urokinase receptorNature Medicine, 2007
- Domain 2 of the Urokinase Receptor Contains an Integrin-interacting Epitope with Intrinsic Signaling ActivityJournal of Biological Chemistry, 2005
- uPAR: a versatile signalling orchestratorNature Reviews Molecular Cell Biology, 2002